nuclear receptor comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-09-18. Numbers and descriptions here follow the published literature rather than marketing material.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small molecule | Studied as a REV-ERB agonist |
| Molecular formula | C20H24ClN3O4S | Reported for the neutral compound |
| Appearance | Off-white to pale yellow solid | Typical research-grade material |
| Solubility | Sparingly soluble in water | Soluble in solvents such as DMSO |
| Common synonyms | SR9009; Stenabolic | Stenabolic is an informal alias |
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.
==== Canada ==== Semaglutide's pharmaceutical data exclusivity period expired in Canada in January 2026. Novo Nordisk failed to pay a required patent maintenance fee, and their patent on the chemical structure of the drug expired in 2020. Several applications and approvals for generic semaglutide followed, both for type 2 diabetes and weight loss. In April 2026, Dr. Reddy's Laboratories received approval to sell generic semaglutide in injectable format in Canada, having applied in February 2024. Later that week, Apotex's generic semaglutide (Apo-Semaglutide) was also approved as an injectable drug. In June 2026, Health Canada approved Sevmia, Apotex's injectable generic semaglutide for weight management in people aged 12 years and above. In July 2026, Aspen Pharmacare received approval for a generic injectable form of the drug for diabetes (Aspen-Semaglutide). Several other applications to sell generic versions have been made, but not yet approved, including by Sandoz, Taro Pharmaceuticals and Teva Pharmaceuticals. Hims & Hers Health expects to partner with an approved manufacturer to market a generic version. Sandoz' 2026 offering would be for diabetes only, while Biocon hopes to offer generic semaglutide for diabetes and weight loss by 2027. Novo Nordisk is considering competing against the new generic drugs with Plosbrio and Poviztra: additional brand names for semaglutide, but marketed at a lower price than Ozempic and Wegovy.
=== Cytotoxic T-cell responses === One of the advantages of DNA vaccines is that they are able to induce cytotoxic T lymphocytes (CTL) without the inherent risk associated with live vaccines. CTL responses can be raised against immunodominant and immunorecessive CTL epitopes, as well as subdominant CTL epitopes, in a manner that appears to mimic natural infection. This may prove to be a useful tool in assessing CTL epitopes and their role in providing immunity. Cytotoxic T-cells recognise small peptides (8-10 amino acids) complexed to MHC class I molecules. These peptides are derived from cytosolic proteins that are degraded and delivered to the nascent MHC class I molecule within the endoplasmic reticulum (ER). Targeting gene products directly to the ER (by the addition of an ER insertion signal sequence at the N-terminus) should thus enhance CTL responses. This was successfully demonstrated using recombinant vaccinia viruses expressing influenza proteins, but the principle should also be applicable to DNA vaccines. Targeting antigens for intracellular degradation (and thus entry into the MHC class I pathway) by the addition of ubiquitin signal sequences, or mutation of other signal sequences, was shown to be effective at increasing CTL responses. CTL responses can be enhanced by co-inoculation with co-stimulatory molecules such as B7-1 or B7-2 for DNA vaccines against influenza nucleoprotein, or GM-CSF for DNA vaccines against the murine malaria model P. yoelii.
== Epidemiology == Few studies have examined the prevalence of FECD on a large scale. First assessed in a clinical setting, Fuchs himself estimated the occurrence of dystrophia epithelialis corneae to be one in every 2000 patients; a rate that is likely reflective of those who progress to advanced disease. Cross-sectional studies suggest a relatively higher prevalence of disease in European countries relative to other areas of the world. Fuchs dystrophy rarely affects individuals under 50 years of age.
Sources: en.wikipedia.org
The Israeli Defense Force (IDF) actively recruits influencers on TikTok and other social media platforms, often with what commentators have dubbed "Thirst traps". In a separate case in 2021, the IDF awarded a TikToker who was one of its military police officers for promoting the image of Israel. She had more followers than IDF spokesperson Ran Kochav or Prime Minister Benjamin Netanyahu. Since 2021, TikTok has created "election centres" on its platform leading up to European Parliament elections. About 30% of EP lawmakers use TikTok to get their messages across and to dispel misinformation. In February 2024, the re-election campaign for then-US president Joe Biden announced that it had opened a TikTok account while taking "advanced safety precautions". Biden posted his first video during Super Bowl LVIII. The move was criticized by a number of lawmakers over security concerns. Since 2022, the Biden administration had briefed TikTokers on news items such as the Russo-Ukrainian war and student debt relief in the United States.
=== Category:EC 2.2 (transfer aldehyde or ketone groups) === Category:EC 2.2.1 Transketolase EC 2.2.1.1 Transaldolase EC 2.2.1.2 Acetolactate synthase EC 2.2.1.6 2-Succinyl-5-enolpyruvyl-6-hydroxy-3-cyclohexene-1-carboxylic-acid synthase EC 2.2.1.9
(No prize had previously been awarded for that year.) They described him as "Linus Carl Pauling, who ever since 1946 has campaigned ceaselessly, not only against nuclear weapons tests, not only against the spread of these armaments, not only against their very use, but against all warfare as a means of solving international conflicts." Pauling himself acknowledged his wife Ava's deep involvement in peace work, and regretted that she was not awarded the Nobel Peace Prize with him.
Sources: en.wikipedia.org
On November 20, 2023, all 8 remaining Connecticut Boston Market locations, located in East Haven, Meriden, West Hartford, Wilton, Stratford, Milford, Bristol, and Newington, were permanently shuttered and issued eviction notices due to unpaid rent. Boston Market and owner Pandya filed for Chapter 11 bankruptcy in December 2023. On January 10, 2024, the company announced that it would allow anyone to open a Boston Market franchise without the usual franchise fees or other buy-in requirements. On January 11, 2024, Boston Market's bankruptcy case was dismissed after the company was unresponsive to court requests. On February 1, 2024, US Foods won its lawsuit against Boston Market, with federal judge Manish Shah saying that Boston Market's defenses in the lawsuit were "gossamer". On February 12, 2024, shortly after its second bankruptcy was dismissed, Boston Market filed for bankruptcy for the third time after losing the US Foods lawsuit. On September 24, 2024, a U.S. bankruptcy judge dismissed Boston Market's appeal regarding a $15 million judgement awarded to US Foods, citing a "lack of prosecution" and Pandya's "bad faith," "delay tactics" and "willful disregard".
Before and during World War II, the primary role of the submarine was anti-surface ship warfare. Submarines would attack either on the surface using deck guns, or submerged using torpedoes. They were particularly effective in sinking Allied transatlantic shipping in both World Wars, and in disrupting Japanese supply routes and naval operations in the Pacific in World War II. Mine-laying submarines were developed in the early part of the 20th century. The facility was used in both World Wars. Submarines were also used for inserting and removing covert agents and military forces in special operations, for intelligence gathering, and to rescue aircrew during air attacks on islands, where the airmen would be told of safe places to crash-land so the submarines could rescue them. Submarines could carry cargo through hostile waters or act as supply vessels for other submarines. Submarines could usually locate and attack other submarines only on the surface, although HMS Venturer managed to sink U-864 with a four torpedo spread while both were submerged. The British developed a specialized anti-submarine submarine in WWI, the R class. After WWII, with the development of the homing torpedo, better sonar systems, and nuclear propulsion, submarines also became able to hunt each other effectively. The development of submarine-launched ballistic missile and submarine-launched cruise missiles gave submarines a substantial and long-ranged ability to attack both land and sea targets with a variety of weapons ranging from cluster bombs to nuclear weapons.
Alfred Stracher (1931-2013) was an American biochemist and the founder and editor-in-chief of Drug Delivery. During his lifetime, he was Distinguished Professor of Biochemistry at SUNY Downstate Medical Center. Alfred Stracher was born in Albany, New York in 1931. He graduated from Rensselaer Polytechnic Institute in 1952 with a Bachelor of Science in Chemistry. He received his PhD in Chemistry from Columbia University in 1956.
== Bibliography == Atwood, David A. (2013). Radionuclides in the Environment. John Wiley and Sons. ISBN 978-1-118-63269-7. Emsley, John (2011). Nature's Building Blocks: An A-Z Guide to the Elements. New York: Oxford University Press, USA. ISBN 978-0-199-60563-7. Hoffman, Klaus (2001). Otto Hahn: Achievement and Responsibility. Springer. Bibcode:2002ohar.book.....H. ISBN 978-0-387-95057-0. Lemire, Robert J. (2001). Chemical Thermodynamics of Neptunium and Plutonium. Amsterdam: Elsevier. ISBN 978-0-444-50379-4. Rhodes, Richard (2012). The Making of the Atomic Bomb (25th Anniversary ed.). New York: Simon & Schuster. ISBN 978-1-451-67761-4. Yoshida, Zenko; Johnson, Stephen G.; Kimura, Takaumi; Krsul, John R. (2006). "Neptunium". In Morss, Lester R.; Edelstein, Norman M.; Fuger, Jean (eds.). The Chemistry of the Actinide and Transactinide Elements (PDF). Vol. 3 (3rd ed.). Dordrecht, the Netherlands: Springer. pp. 699–812. doi:10.1007/1-4020-3598-5_6. ISBN 978-1-4020-3555-5. Archived from the original (PDF) on January 17, 2018.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.
No. SR9009 is frequently mislabeled as a SARM in online discussions, but it does not target androgen receptors. Its known mechanism involves REV-ERB nuclear receptors and circadian-metabolic gene regulation.
Human clinical data are very limited. There is no approved human use, and safety and efficacy in people are not established. Most evidence comes from preclinical models, so effects observed in animals may not apply to humans.
The most common approach is liquid chromatography-tandem mass spectrometry, often after extraction from blood, urine, or tissue. Ultraviolet detection and nuclear magnetic resonance spectroscopy are used mainly for reference material characterization. Isotope-labeled internal standards improve accuracy.